These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 26620208)

  • 1. Anti-angiogenic alternatives to VEGF blockade.
    Khan KA; Bicknell R
    Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor: biology and therapeutic applications.
    Ho QT; Kuo CJ
    Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor angiogenesis and anti-angiogenic therapy.
    Kubota Y
    Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis and angiogenesis inhibitors in cancer.
    Giavazzi R; Taraboletti G
    Forum (Genova); 1999; 9(3):261-72. PubMed ID: 10504172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
    Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
    Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
    Kerbel RS; Viloria-Petit A; Klement G; Rak J
    Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
    Moreira IS; Fernandes PA; Ramos MJ
    Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
    Lindsay CR; MacPherson IR; Cassidy J
    Future Oncol; 2009 May; 5(4):421-32. PubMed ID: 19450171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
    Jászai J; Schmidt MHH
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
    Niu G; Chen X
    Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.